AVIOQ, Inc. is a company that specializes in the development and manufacturing of diagnostic tests, particularly in the field of in vitro diagnostics (IVD). AVIOQ is known for its expertise in immunoassay technology and has developed assays for various infectious diseases, including HIV (Human Immunodeficiency Virus).
One of AVIOQ’s notable products is the AVIOq HIV-1 Microelisa System, an enzyme immunoassay (EIA) kit used for the detection of antibodies to HIV-1 (HIV Type 1) in human serum or plasma. This diagnostic test is an important tool in the diagnosis and monitoring of HIV infection.
Avioq is an expanding in-vitro diagnostic medical device company Specializing in the development, production and distribution of quality products, as well as providing flexible contract development and manufacturing services in an FDA licensed and ISO 13485 certified environment
Address:
104 T.W. Alexander Drive
Building 6
P.O. Box 12808
Research Triangle Park NC 27709
Product Approval Dates
26‐MAR‐2012 Human T‐Lymphotropic Virus Types I & II (HTLV‐I and HTLV‐II/Enzyme Immuno Assay (EIA)/Lysate)
Avioq Product Line
VioOne HIV Profile
• FDA Approved and CE Mark
• ELISA for confirmation and differentiation of individual antibodies directed to various gene products of HIV-1 and HIV-2
• Human Serum or Plasma
• Proven microelisa technology, microwell solid phase
AVIOQ HTLV-I/II Assay
FDA Licensed and CE Marked for:
• Serum and Plasma (Clinical or Donor Testing)
• Serum and Plasma (Deceased Organ and Tissue Donors)
Total incubation time only 2 hours, 30 minutes
AVIOQ HIV-1 Assay
FDA Approved for:
• Serum
• Plasma
• Oral Fluid and Dried Blood Spot
GMP Recombinant Proteins and Synthetic Peptides
• GMP compliant
• Bulk quantities available
• Avioq maintains a FDA (BLA) licensed and ISO 13485 certified manufacturing facility